PLoS Pathogens · 2022 · 123 citations · 45 references
Veterinary MedicineImmunologyInfectious DiseasesImmunology Of Infectious DiseasesImmunopathologyInflammationCytokine BiologyImmune-mediated Sequelae Of InfectionInflammation In Infectious DiseaseInflammatory Cell ResponsesPulmonary InflammationT Cell BiologyCd8 Positive T CellsCd8 T Cell ActivationImmune MarkersLung Function DeclinePost-infection SequelaeSars-cov-2 InfectionSevere Acute Respiratory SyndromeT Cell-mediated Lung Inflammation
As of January 2022, at least 60 million individuals are estimated to develop post-acute sequelae of SARS-CoV-2 (PASC) after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). While elevated levels of SARS-CoV-2-specific T cells have been observed in non-specific PASC, little is known about their impact on pulmonary function which is compromised in the majority of these individuals. This study compares frequencies of SARS-CoV-2-specific T cells and inflammatory markers with lung function in participants with pulmonary PASC and resolved COVID-19 (RC). Compared to RC, participants with respiratory PASC had between 6- and 105-fold higher frequencies of IFN-γ- and TNF-α-producing SARS-CoV-2-specific CD4+ and CD8+ T cells in peripheral blood, and elevated levels of plasma CRP and IL-6. Importantly, in PASC participants the frequency of TNF-α-producing SARS-CoV-2-specific CD4+ and CD8+ T cells, which exhibited the highest levels of Ki67 indicating they were activity dividing, correlated positively with plasma IL-6 and negatively with measures of lung function, including forced expiratory volume in one second (FEV1), while increased frequencies of IFN-γ-producing SARS-CoV-2-specific T cells associated with prolonged dyspnea. Statistical analyses stratified by age, number of comorbidities and hospitalization status demonstrated that none of these factors affect differences in the frequency of SARS-CoV-2 T cells and plasma IL-6 levels measured between PASC and RC cohorts. Taken together, these findings demonstrate elevated frequencies of SARS-CoV-2-specific T cells in individuals with pulmonary PASC are associated with increased systemic inflammation and decreased lung function, suggesting that SARS-CoV-2-specific T cells contribute to lingering pulmonary symptoms. These findings also provide mechanistic insight on the pathophysiology of PASC that can inform development of potential treatments to reduce symptom burden.
45
Persistent Symptoms in Patients After Acute COVID-19
Angelo Carfì, Roberto Bernabei, Francesco Landi · JAMA · 2020 · 4.8K citations · Full text
Veterinary Medicine, Infectious Diseases, Internal Medicine +9
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection
Jennifer M. Dan, José Mateus, Yu Kato et al. · Science · 2021 · 3K citations · Full text
Effective treatment of severe COVID-19 patients with tocilizumab
Xiaoling Xu, Mingfeng Han, Tiantian Li et al. · Proceedings of the National Academy of Sciences · 2020 · 2.8K citations · Full text
Attributes and predictors of long COVID
Carole H. Sudre, Benjamin Murray, Thomas Varsavsky et al. · Nature Medicine · 2021 · 2.6K citations · Full text